


# CJSB462B12201 mCRPC - Study Design



Arm 1

JSB462 100 mg QD + AAA617 (7.4GBq)

Arm 2

JSB462 300 mg QD + AAA617 (7.4GBq)

Arm 3

AAA617 (7.4GBq)

R  
5:5:3

An interim safety lock will be performed in the first randomized participants (~6-10 participants in Arm 1, ~6-10 in Arm 2 and ~3-6 in Arm 3).

All patients must receive **androgen deprivation therapy** (per physician's choice) to maintain castrate levels of testosterone during the study.  
[Testosterone < 50 ng/dL or < 1.7 nmol/L]